Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Trimmed by New York State Common Retirement Fund

Key Points

• The New York State Common Retirement Fund reduced its holdings in Enliven Therapeutics by 60.8%, leaving it with 9,797 shares valued at $193,000.
• Enliven Therapeutics reported a loss of ($0.57) earnings per share for the last quarter, missing analyst expectations by ($0.06).
• Multiple analysts have given Enliven Therapeutics a buy rating, with price targets ranging from $27.00 to $52.00, indicating a generally positive outlook for the stock.

New York State Common Retirement Fund trimmed its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 60.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,797 shares of the company's stock after selling 15,226 shares during the period. New York State Common Retirement Fund's holdings in Enliven Therapeutics were worth $193,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ELVN. Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after purchasing an additional 2,630 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $97,000. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth approximately $112,000. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth approximately $200,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $21.20 on Friday. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The stock has a market capitalization of $1.04 billion, a PE ratio of -11.04 and a beta of 0.83. The firm has a 50 day simple moving average of $20.41 and a 200-day simple moving average of $20.19.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $21.40, for a total value of $267,500.00. Following the completion of the transaction, the insider owned 965,188 shares in the company, valued at $20,655,023.20. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the transaction, the chief executive officer directly owned 952,892 shares in the company, valued at $21,135,144.56. This represents a 1.29% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 116,111 shares of company stock worth $2,371,551. Corporate insiders own 25.90% of the company's stock.

Analyst Ratings Changes

ELVN has been the subject of a number of recent research reports. HC Wainwright upped their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 price target for the company. Robert W. Baird increased their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, Jones Trading reduced their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and an average target price of $41.20.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.